BRISBANE, Calif., Aug. 4, 2011 /PRNewswire/ — InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2011. InterMune also highlighted its recent business and clinical development activities, as well as the status of preparations for the launches of Esbriet® (pirfenidone) in the European Union.
Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, “The second quarter was highlighted by the rapid and substantial progress we made in our preparations to launch Esbriet in the EU in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis, or IPF. We are now in the final stages of preparing to make Esbriet available to patients in Europe, beginning with Germany in September, in a launch that will coincide with the Annual Congress of the European Respiratory Society. We are pleased to report that our German organization is fully staffed, with our sales force undergoing training this month. The launch in Germany will be followed by a series of Esbriet launches in the other major EU countries through 2012.”
Read entire article at:
or visit www.ipftoday.com for more news